European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading

MT Newswires Live10-14

European equities traded in the US as American depositary receipts kicked off the week tracking higher late Monday morning, rising 0.44% to 1,432.38 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by telecommunications operator VEON (VEON) and software firm SAP (SAP), which rose 2.7% and 1.1%, respectively. They were followed by pharmaceutical company Sanofi (SNY) and telecommunications company Nokia (NOK), which were up 0.8% and 0.6%, respectively.

The decliners from continental Europe were led by biopharmaceutical company Genfit (GNFT) and internet browser company Opera (OPRA), which fell 3.1% and 2.2%, respectively. They were followed by biopharmaceutical company Grifols (GRFS) and biotech firm Evaxion Biotech (EVAX), which lost 1.8% and 1.1%, respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical companies Biodexa Pharmaceuticals (BDRX) and Verona Pharma (VRNA), which increased 2.3% and 1.6%, respectively. They were followed by insurance company Prudential (PUK) and biopharmaceutical company Amarin (AMRN), which were up 0.7%, each.

The decliners from the UK and Ireland were led by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company NuCana (NCNA), which dropped 16% and 6.2%, respectively. They were followed by biopharmaceutical company Adaptimmune Therapeutics (ADAP) and pharmaceutical company Silence Therapeutics (SLN), which were down 2.2% and 1.9%, respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment